Article
Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study.
Cancer research and treatment - 1 Oct 2023
Kim Taeyun, Jang Tae Won, Choi Chang Min, Kim Mi-Hyun, Lee Sung Yong, Chang Yoon Soo, Lee Kye Young, Kim Seung Joon, Yang Sei Hoon, Ryu Jeong Seon, Lee Jeong Eun, Lee Shin Yup, Park Chan Kwon, Lee Sang Hoon, Jang Seung Hun, Yoon Seong Hoon, Oh Hyung-Joo
Abstract excerpt
PURPOSE: This study aimed to report the final analysis of time-on-treatment (TOT) and overall survival (OS) in patients with advanced-stage epidermal growth factor receptor (EGFR)+ non-small cell lung cancer (NSCLC) who received sequential afatinib and osimertinib and to compare the outcomes with other second-line regimens (comparator group). MATERIALS AND METHODS: In this updated report, the existing medical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.